Indeed, such a connection between Sorafenib and the mTOR pathway has also been observed in hepatocellular carcinoma where treatment with Sorafenib in patients with increased PI3K/mTOR pathway activity results in reduced relapse rates52–54. This evidence concerns the gene MTOR and hepatocellular carcinoma.